European Journal of Cancer

Article	Citations
Editorial Board	422
Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids	281
Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Jour	203
Editorial Board	179
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	176
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	157
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	152
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	150
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study	136
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma	136
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	125
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	113
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	109
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	108
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	102
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	101
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	96
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	92
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	90
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	87
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	87
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	87
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	84
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	83
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	80

300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers	79
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	78
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	75
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	74
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	72
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	71
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	70
Macular type of primary cutaneous B-cell lymphoma: extension of the clinical and histopathological patterns	69
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	69
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	67
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	66
Spectrum of dermo-epidermic cutaneous gamma-delta lymphomas from a single center: clinical and phenotypic analysis of an heterogenous lymphoproliferative disorder	66
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	64
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	63
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	62
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	62
Discovery of Essential microRNA in Prostate Cancer Cells	61
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	61
Non-clinical identification and characterization of KRAS G12D inhibitors	60
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas	60
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	60
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	60
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	60
Impact of establishing a genetic clinic in conjunction with clinical practice in India	59
Contrast-enhanced mammography (CEM) with magnetic tracer as an alternative to MRI	58
Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients	58
The Punjab breast cancer AI-digital project: Implementing Artificial Intelligence-based triaging at scale for population-level screening of breast cancer	58
Impact of an Online Educational Activity on Oncologists’ Knowledge and Competence Regrading the Optimal Use of Adjuvant Treatment in Breast Cancer	57
Clinical and Experimental investigation of AKT1/2/3 isoforms indicated non-redundant isoform specific role in driving stemness and Cisplatin resistance in TNBCs	56
The Sponsor Acknowledgment and Introduction	53
Efficiency of textile photodynamic therapy for mycosis fungoides	53
Interobserver variation in the assessment of HER2 low expression in breast cancer: can we improve by adjusting criteria? An international interobserver study	53
Experience of a supra-regional cutaneous lymphoma centre during the COVID-19 pandemic	52
An update on health-related quality of life from the PROCLIPI study	51
Neoadjuvant treatment for breast cancer patients in a Venezuelan breast center. Pathologic complete response: is it worth it?	51
SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients	51
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	51
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	51
Home based care for terminal cancer patients: study from rural part of India	50
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	50
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	50
Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials	49
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	49
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma	49
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics	48
Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities	48
New drugs and options can enhance patient outcomes: But can they also erode them?	48
Granulomatous slack skin: clinical retrospective study of 8 cases of the Cutaneous Lymphoma French Study Group	48
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma	48
Cancer and immunotherapy: a role for microbiota composition	47

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	47
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	46
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	46
Troponin increase during immunotherapy: Not always myocarditis	46
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 tr	46
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	46
Perspectives on the role of “-Omics” in predicting response to immunotherapy	45
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	45
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters	45
10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis	45
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	45
Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck	44
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants	44
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry	44
Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity	44
Gene expression-based prediction of pazopanib efficacy in sarcoma	44
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01	43
DNA methylation markers in the detection of hepatocellular carcinoma	43
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials	43
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	43
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System	43
Life-threatening skin reaction with Enfortumab Vedotin: Six cases	43
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	42
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	42
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life	42
Recent advances and future strategies in first-line treatment of ES-SCLC	41
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	41
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study	41
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients	41
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling,	41
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164	41
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patien	41
Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma	41
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer	41
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	41
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma	41
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)	41
Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy	40
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer	40
Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward	39
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations	39
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer	39
Immunotherapy for brain metastases and primary brain tumors	39
Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues	39
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	39
Ocular, meningeal and cerebral involvement of mycosis fungoides associated with an immunophenotypic switch from CD4+ to CD8+	38
Photodynamic therapy for the treatment of primary cutaneous B-cell marginal zone lymphoma: a series of 4 patients	38
First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type	38
Real-life evaluation of efficacy and tolerability of chlormethine gel in Italian centers	38
Characteristics and clinical outcomes of breast cancer patients under different modalities of breast-conserving surgery and lymph node management in China	38
ERBB2 mRNA expression in HER2-low breast cancer	38
Peripheral blood neutrophil/lymphocyte ratio as a prognostic factor in triple negative breast cancer	37
Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype	37
A multidisciplinary approach to the enhancement of quality of life of breast cancer patients in the South-west, Nigeria	37
Initial experience with targeted axillary dissection (TAD) guided by ultrasound in early-stage node positive breast cancer patients undergoing upfront surgery	37
High PD1 expression H score is associated with Sézary diagnosis: study of 91 patients with erythroderma	37
PD1 regulates T cell exhaustion phenotypes and disease aggressiveness in CTCL	37
Racial disparity and time to treatment initiation effects on survival differences in breast cancer: a DAGs-based review protocol for a systematic review of cohort studies	37
Evaluation of the role of different cell populations in mycosis fungoides microenvironment as a tool for biomarker identification for disease progression and individualized therapy	37
Targeted axillary dissection or sentinel node biopsy after neo-adjuvant treatment in clinically node positive patients – the West of Scotland experience	36
Contrast enhanced mammography in further assessment of screen-detected breast cancer	36
Efficacy and safety of abemaciclib in the treatment of HR+ HER2-advanced breast cancer: real world data	35
Contrast Enhanced Mammography in Breast Cancer Surveillance	35
Editorial Board	35
Characterisation of adaptive responses of cancer cells to oxaliplatin by analysis of leading edge genes from genes set enrichment analysis	35
The microbiome of patients with breast cancer; observational study on the microbiome composition of breast cancer patients and the effects of chemotherapy treatment on the microbiome	35
Primary cutaneous follicle center lymphoma with secondary systemic evolution	35
Title Page	35
HX301, a potent CSF1R inhibitor, suppresses tumor associated M2 macrophage (TAM), enhancing tumor immunity and causing transit tumor inhibition in syngeneic EMT-6 tumors	35
Mode of Recurrence/ Metastasis Detection in Breast cancer survivors	35
Quality of life in cutaneous lymphoma varies by lymphoma type	34
Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742	34
Is there microbial dysbiosis in CTCL? A pilot study	34
HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study	33
A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study	33
A novel computational pathology approach for identifying gene signatures prognostic of disease-free survival for papillary thyroid carcinomas	33
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer	33
Multimodal therapy with bexarotene and extracorporeal photopheresis for T-cell cutaneous lymphomas: real-life experiences in Argentina	33
Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: interim analysis of the German non-interventional MINT study	33
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial	33

MYC inhibition by Omomyc unveils a prognostic gene signature in Melanoma	33
Loss of RHOA impairs lenalidomide antitumor activity in mantle cell lymphoma	33
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1	33
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis	32
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors	32
Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization – Implications in treatment outcomes	32
Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998-2020 – A Danish nationwide population-based cohort study	32
Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer	32
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience	31
Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis	31
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer	31
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment	31
Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience	31
Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial	31
Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study	31
Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC	31
Placing the patient at the heart of discovery science	31
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies	31
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA	30
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours	30
Reliability of patient-reported toxicities during adjuvant chemotherapy	30
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme	30
Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation	30
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients	30
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience	30
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas	29
121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study	29
100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild	29
237 (PB225): Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces Immunogenic Cell Death	29
444 (PB432): First-in-human phase 1 study of RGT-264, a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor in patients (pts) with advanced solid tumors	29
344 (PB332): Systematic assessment of ALC1 depletion as a therapeutic approach in homologous recombination deficient cells	29
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients	29
294 (PB282): Suppression of Glioblastoma Progression by FDA-Approved Central Nervous System-Accumulating Drugs via Autophagy Modulation and ER Stress-Induced Apoptosis	29
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lu	29
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies	29
Systematic nutritional screening and assessment in older patients: Rationale for its integration into oncology practice	28
26 (PB014): Development of Tumour-specific CD146 CAR-T Cells for Targeted Cancer Immunotherapy of Solid Tumours	28
158 (PB146): Immune Monitoring in Preclinical Tumor Mouse Models Using Spectral Analyzer Technology	28
A-153 Primary cutaneous T-cell lymphoma not otherwise specified (NOS) uncovering a novel RAB27A variant in Griscelli syndrome type 2	28
Peer Review Policy for the European Journal of Cancer (EJC)	28
299 (PB287): Lomitapide enhances cytotoxic effects of temozolomide in chemoresistant glioblastoma	28
Editorial Board	28
A-206 4 cases of pediatrics mycosis fungoides revealed by recalcitrant psoriatic palmoplantar keratoderma	28
A-186 Molecular Insights into Primary Cutaneous CD30+ T-cell Lymphoproliferative Disorders: Wnt/Beta-Catenin Pathway Activation and Prognostic Role of TP53 mutations?	28
443 (PB431): A Sub Analysis of Clinical Study of Tomaralimab, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylat	28
43 (PB031): MBT-C101, a first-in-class, selective, and potent HSP90 chaperonemediated degrader of PI3Ka	28
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer	28
A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study	28
A-170 Is there microbial dysbiosis in CTCL? A pilot study	28
Norwegian general population normative data for the European Organization for Research and Treatment of Cancer questionnaires: the Quality of Life Questionnaire-Core 30, the Sexual Health Questionnair	27
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)	27
Computerizing the first step of the two-step algorithm in dermoscopy: A convolutional neural network for differentiating melanocytic from non-melanocytic skin lesions	27
Nivolumab induces long-term remission in a patient with fusariosis	27
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours	27
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study	27
Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis	27
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years	27
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered dise	27
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer	27
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial	27
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study	26
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics	26
A machine learning tool for identifying non-metastatic colorectal cancer in primary care	26
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases	26
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)	26
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients	26
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months	26
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas	26
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy	25
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study	25
OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis	25
An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations	25
Eliminating the Immunotoxicity of Interleukin-12 through Protease-Sensitive Masking	25
Nipple-sparing mastectomy with primary breast reconstruction: Breast cancer local recurrence according to molecular subtype	25
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study	25
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy	25
MaThAI: A MultiModal imaging combining Mammography and Thermalytix for better prioritization of mammography scans to detect early malignancies	25
Response to letter entitled: Re: Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study	25
Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles	25
Coverage and Socio-economic inequalities in breast cancer screening in Low- and Middle-Income Countries: Analysis of Demographic and Health Surveys between 2010 and 2019	25
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study	25
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer	25
The relationship among bowel FDG-PET uptake, pathological complete response, and eating habits in breast cancer patients undergoing neoadjuvant chemotherapy	25
Liquid biopsy assessment in primary cutaneous diffuse large B-Cell lymphoma- leg type	25
Intraoperative ultrasound is accurate for guiding breast conservative surgery in non-palpable ductal carcinoma in situ of the breast	25
One-step nucleic acid amplification assay in palpable and non-palpable breast tumours	25
Editorial Board	24
The role of the certified surgeon-oncologist in improving the diagnosis and operative treatment of patients with breast tumors	24
Understanding the function of CD30 in cutaneous T-cell lymphoma: implications for therapy and prognosis	24
Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors	24
Correlation between weight and Recurrence Score in a cohort of HR+ve/ HER2-ve early breast cancer patients: a retrospective analysis	24
High intraindividual variability of CD30 expression in mycosis fungoides: implications for diagnostic evaluation and therapy	24
Exposure-response relation in metastatic colorectal cancer organoids after high-dose short-term tyrosine kinase inhibitor exposure	24
Intravascular relapse of an extra-nodal NK/T-cell lymphoma, nasal-type, presenting as diffuse and eruptive telangiectasia	24
Cryoablation in Breast Cancer Care – an analysis from a Single Multi-Disciplinary Unit in Southern Africa	24